{
  "Cancer Histology Subtype (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2615, 
        2619
      ]
    }
  ], 
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1885, 
        1894
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2620, 
        2629
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1012, 
        1035
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1369, 
        1392
      ]
    }
  ], 
  "Comments Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4834, 
        4854
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5908, 
        5928
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1812, 
        1839
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3241, 
        3268
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3353, 
        3380
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        523, 
        552
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2245, 
        2251
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2806, 
        2812
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3418, 
        3426
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3724, 
        3732
      ]
    }
  ], 
  "Neoplasm Grade Value (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1907, 
        1909
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2252, 
        2265
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2813, 
        2826
      ]
    }
  ], 
  "Specimen Identifier (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3055, 
        3057
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4480, 
        4482
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PATHLAB_LIS|HOSPITAL 7^9999^MOH|PIMS|CCO|20160503112700|E3B45DDCAB65C0F9A0AFABD677128D6206EE81A8|ORU^R01|999999999999|P|2.5|||||||||||\nPID|1||G9999999^^^^CMR^HOSPITAL 7&9999&MOH~G9999999^^^^MRN^HOSPITAL 7&9999&MOH~9999999999&XX&ON^^^^JHN||XXXXXXX^XXXXXXXXX^^^^^||99999999|F|||9 XXXXXX XXXXXX XX^^XXXXXXXXXXX^XX^X9X 9X9^999|||||||||||||||||||N|||||||||||\nOBR|1||BZ00604348|11529-5^Surgical Pathology Study Report^LN^BX^Biopsy^L|||20160419|||23434^XXXXXX^XXXXXXXX^XXXXXXX^^XX.||||||||||||20160504|||C||||||||\n\n\n\n\n\n\n\nPath report.gross description\n\n#1 - Specimen consists of 4 tan tissue coresnE\\measuring 10, 15, 17 and 18 mm in length by lessnE\\than 1 mm in diameter and no fragments. EmbeddednE\\in toto.nE\nE\\At the time of embedding MLT found 4 cores and nonE\\fragments.nE\nE\\#2 - Specimen consists of 4 tan tissue coresnE\\measuring 5, 10, 14 and 14 mm in length by lessnE\\than 1 mm in diameter and no fragments. EmbeddednE\\in toto.nE\nE\\At the time of embedding MLT found 4 cores and nonE\\fragments.nE\\\n\n\nPath report.relevant Hx\n\nSpecimen #1 (site and type): Right breast,nE\\11 oclocknE\\Specimen #2 (site and type): Left breast,nE\\4 oclocknE\nE\\Ischemic Time: <5 minnE\nE\\Fixation Used: 10% NBFnE\nE\\Fixation Duration: 35 hoursnE\\\nScreening mammogram, right nodule, irregular,nE\\12 mmnE\\Left densitynE\\Site #1 number of cores = 4nE\\Site #2 number of cores = 4nE\\\n\n\nPath report.relevant Hx\n\nBurlington Ultrasound and RadiologynE\\Phone: 1-905-637-7606nE\\Fax: 1-905-637-2139nE\nE\\Referring Specimen ID #: N/AnE\\*Block #: N/AnE\\Specimen Type: Needle core biopsynE\\Specimen Site: Right breast, 11 oclocknE\\Diagnosis: Infiltrating duct carcinoma, NOS,nE\\grade II (preliminary grade) with micro focus ofnE\\ductal carcinoma in situ changesnE\\*If more than one block was submitted please seenE\\additional report.nE\\\n\n\nPath report.final diagnosis\n\n#1 The sections show an infiltrating ductnE\\carcinoma, NOS, grade II (preliminary grade),nE\\with micro focus of ductal carcinoma in situnE\\changes, nuclear grade 2. On immunohistochemistrynE\\workup the infiltrating carcinoma cells stain E-nE\\cadherin positive and p63 predominantly negative.nE\\The duct showing DCIS components are rimmed bynE\\myoepithelial cells (p63 positive).nE\nE\\#2 The sections show benign breast tissue,nE\\unremarkable. On immunohistochemistry workup thenE\\ducts and tubules present are rimmed bynE\\myoepithelial cells (p63 positive and SMMnE\\positive). The ductal cells stain E-cadherinnE\\positive. This result supports the diagnosis ofnE\\benign breasts tissue, unremarkable.nE\nE\nE\\#1 - BREAST RIGHT, 11 OCLOCK, NEEDLE COREnE\\BIOPSY:nE\\- INFILTRATING DUCT CARCINOMA, NOS, GRADEnE\\II (PRELIMINARY GRADE) WITH MICRO FOCUS OFnE\\DUCTAL CARCINOMA IN SITU CHANGESnE\\- ER, PR, HER-2/NEU PENDINGnE\nE\\#2 BREAST LEFT, 4 OCLOCK, NEEDLE CORE BIOPSY:nE\\- BENIGN BREAST TISSUE, UNREMARKABLEnE\nE\\******PATHOLOGIC/RADIOLOGIC CORRELATION*****nE\nE\\THE SECTIONS OF THIS CASE HAVE BEEN REVIEWED BYnE\\THE PATHOLOGY/RADIOLOGY PANEL AND CORRELATED WITHnE\\THE RADIOLOGIC FINDINGS. RADIOLOGY PANEL CONSISTSnE\\OF DR. C. L. LOUISY.nE\nE\\THE RADIOLOGICAL/PATHOLOGICAL FINDINGS: CorrelatenE\nE\\RECOMMENDATION OF MULTIDISCIPLINARY PANEL:nE\\Surgical consultation preop localization shouldnE\\be considerednE\\\n\n\nPath report.final diagnosis\n\nER: PositivenE\\PgR: PositivenE\\HER2 IHC: EquivocalnE\\HER2 FISH: Non-amplifiednE\\\n\n\nPath report.final diagnosis\n\nER Result: PositivenE\\Percentage of invasive tumour cells with nuclearnE\\positivity: 100nE\\Average intensity of staining: StrongnE\\External Control staining: AdequatenE\\Internal Control staining: AbsentnE\nE\\ER antibody used: EP1 Antibody, Dako, PT LinknE\\High pH, EnVision FLEX Detection, DABnE\nE\\(PgR)nE\\PgR Result: PositivenE\\Percentage of invasive tumour cells with nuclearnE\\positivity: 90nE\\Average intensity of staining: StrongnE\\External Control staining: AdequatenE\\Internal Control staining: AbsentnE\nE\\PgR antibody used: PgR 636 Antibody, Dako, PTnE\\Link High pH, EnVision FLEX Detection, DABnE\nE\\HercepTestnE\\HER2/neu Interpretation: Equivocal (2+)nE\\External QC: AdequatenE\nE\\HER2 antibody used: Health Canada ApprovednE\\HercepTest Kit, DakonE\nE\\IQFISHnE\\QC:?Adequate?nE\\Heterogenous Signals:?Absent?nE\nE\\Number of cells counted: 30nE\\Average number of HER2/neu signals per nucleusnE\\counted: 2.1nE\\Average number of CEP17 signals per nucleusnE\\counted: 1.6nE\\The ratio of HER2neu/CEP17: 1.3nE\nE\\HER2/neu FISH Interpretation: Non-amplifiednE\\HER2/neu FISH read and reported by:nE\\?MLT: J. Vandenberg?nE\\?Pathologist: Dr. L. Elavathil?nE\nE\\Dual Probe(s) Used: HER2/CEN-17 Probe MixnE\\Method: Dako, HER2 IQFISH pharmDx Kit, CodenE\\K5731, FDA and Health Canada approved.nE\nE\\Please see Laboratory Reference Ranges onnE\\Following PagenE\nE\\BREAST PATHOLOGY CONSULTANT:nE\\Dr. Leela Elavathil, MBBS, FRCPnE\\<Electronic Signature on File>nE\nE\nE\\\n\n\nPath report.comments\n\nThis report is available in ClinicalConnectnE\\(OLIS) and Dynacares eResults.nE\nE\\Cold ischemic time: <5 (minutes)nE\nE\\Total fixation time: 35 (hours)nE\nE\\Cold ischemia and fixation times meet thenE\\requirements specified in the latest versionnE\\(2013) of the ASCO/CAP guidelines for reportingnE\\results of the biomarker testing of specimensnE\\from patients with carcinoma of the breast.nE\nE\\X YesnE\nE\\All breast biomarkers are validated with tissuenE\\fixed in 10% NBF for 6 to 72 hours, according tonE\\2013 ASCO/CAP guidelines. The methods are notnE\\validated for shorter or longer fixation in NBF,nE\\other fixatives, cold ischemic time more than 60nE\\minutes, treatment of tissue with microwaves,nE\\decalcification or the use of mercurochrome. IfnE\\the handling of the sample falls outside of thenE\\acceptable parameters, the results will benE\\considered non-validated.nE\\Dynacare Next Molecular and Cellular PathologynE\\Laboratory participates in the HER2/neunE\\Provincial Quality Assurance Program as well asnE\\EQA programs with cIQc and IQMH.nE\\\n\n\nPath report.comments\n\nReporting Results on ER and PgR TestingnE\nE\\Result:  PositivenE\\Criteria: Immunoreactive tumor cells presentnE\\(>/=1%)nE\\Comments - The percentage of immunoreactivenE\\cells may be determined by visualnE\\estimation or quantification. Quantification cannE\\be provided by reporting the percentage ofnE\\positive cells or by a scoring system, such asnE\\the Alfred score or H score.nE\nE\\Result:  NegativenE\\Criteria: <1% immunoreactive tumor cells presentnE\nE\\Reporting Results of HER2 Testing bynE\\Immunohistochemistry (IHC)nE\nE\\Result:   Negative (Score 0)nE\\Criteria:  No staining observed or incomplete,nE\\faint/barely perceptible membrane staining innE\\</=10% of invasive tumor cellsnE\nE\\Result:  Negative (Score 1+)nE\\Criteria: Incomplete, faint/barely perceptiblenE\\membrane staining in >10% of invasive tumornE\\cells*nE\nE\\Result:  Equivocal (Score 2+)**nE\\Criteria: Incomplete and/or weak to moderatenE\\circumferential membrane staining in >10% ofnE\\invasive tumor cells or Complete, Intense,nE\\circumferential membrane staining in </=10% ofnE\\invasive tumor cells*nE\nE\\Result:  Positive (Score 3+)nE\\Criteria: Complete, Intense, circumferentialnE\\membrane staining in >10% of invasive tumornE\\cells*nE\nE\\*Readily appreciated using low-power objectivenE\\and observed within a homogenous and contiguousnE\\population of invasive tumor cells.nE\\**Must order reflex in situ hybridization testnE\\(same specimen) or new test (new specimen ifnE\\available, using immunohistochemistry or in situnE\\hybridization).nE\nE\\Reporting Results of HER2 Testing by in SitunE\\Hybridization (dual-probe assay)nE\nE\\Result:   Negative (not amplified)nE\\Criteria:  HER2/CEP17 ratio <2.0 AND averagenE\\HER2 copy number <4.0 signals/cellnE\nE\\Result:   Equivocal*nE\\Criteria:  HER2/CEP17 ratio <2.0 AND averagenE\\HER2 copy number >/=4.0 but < 6.0 signals/cell*nE\nE\\Result:   Positive (amplified)nE\\Criteria:  HER2/CEP17 ratio >2.0** (regardlessnE\\of average HER2 copy number) ornE\\Average HER2 copy number >/=6.0 signals/cell**nE\\(regardless of ratio)nE\nE\\*Must order a reflex test (same specimen usingnE\\immunohistochemistry),nE\\Test with alternative in situ hybridizationnE\\chromosome 17 probe, or order a new test (newnE\\specimen if available, using immunohistochemistrynE\\of in situ hybridization).nE\\**Observed in a homogenous and contiguousnE\\population of >/= 10% of invasive tumor cells.\n\n\n"
}